Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEP
NCT07368153Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Epstein-Barr virus infection (2 arms), sponsored by University Hospital Basel. Primary endpoints: Incidence of adverse events at 16 weeks, Incidence of serious adverse events at 16 weeks and 2 more. Started Aug 2026; status: recruiting.
02
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07368153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368153.